DMRA today

$23.25-$0.90 (-3.73%)close Nov 11, 2026

Trend

DailyUptrend (confirmed)

4 hourDescending Triangle

1 hourBearish

15 minStrong Bearish

5 minStrong Bearish

Daily trend turns down below $15.00

Key levels

Resistance$29.18

Resistance$25.63

Support$23.21

Support$20.75

About Damora Therapeutics

Damora Therapeutics is a preclinical biopharmaceutical company developing antibody therapies for hematologic disorders, specifically myeloproliferative neoplasms. Its lead program, DMR-001, targets mutant calreticulin for essential thrombocythemia and myelofibrosis, with two additional antibody programs in earlier development. The company operates in the United States and licenses its programs from Paragon Therapeutics.

Based on the company's 10-K filed Mar 19, 2026.

NASDAQ · Healthcare

Galecto, Inc. (DMRA)

$23.25-0.90 (-3.73%)

WATCHLISTGrade: BRisk: MEDIUM

1D 5D1M1Y 5Y MaxSign up for all timeframes

High25.07

Low23.20

Open24.15

Volume512K

Avg Vol460K

VWAP24.05

30d High24.15

30d Low18.43

30d Chg+14.93%

See full chart with real-time data

What Is the Price Target for DMRA?

SEPT Low Target

$36.12

SEPT Mid Target

$42.50

SEPT High Target

$48.87

Analyst Consensus

$42.50

Current: $23.70Upside: +79.3%Confidence: 85%Method: Analyst Consensus

Is DMRA a Buy or Sell Right Now?

Investability Score

WATCHLIST12-18 months

Thesis

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DMRA.

Start Free Trial →

Is DMRA Overvalued or Undervalued?

Valuation Verdict

FAIR

Methods Used

P/B, PEG, Analyst Consensus

Fair Value

$32.38

Moat Score

NONE

2/9

Piotroski Score

-19.7

Altman Z-Score

What Is Smart Money Doing with DMRA?

Insider Signal

NEUTRAL

1 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

HIGH

Signal: HIGH_SHORT_INTEREST

Recent Insider Activity

Name	Title	Type	Shares	Value	Date
Jarrett Jennifer	director officer	Buy	12,500	$253K	Sep 25, 2026

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

DMRA Growth Story

Revenue YoY

N/A%

3yr Revenue CAGR

N/A%

EPS Growth YoY

48.64%

FCF Growth YoY

49.5%

Revenue Trend

UNKNOWN

Dark Pool Trades for DMRA

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for DMRA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

Time	Price	Size	Value	Side
21:00:23	$23.25	3,206	$$75K	SELL
21:00:23	$23.25	2,485	$$58K	SELL
21:00:23	$23.25	1,400	$$33K	SELL
21:00:23	$23.25	2,600	$$60K	SELL
20:58:34	$23.25	1,300	$$30K	SELL

5 dark pool trades shown · $$256K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Galecto, Inc. (DMRA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

DMRA — frequently asked questions

What is DMRA stock price today?

Galecto, Inc. (DMRA) is at $23.25, down 3.73% (-$0.90) at the Nov 11, 2026 close.

Why is DMRA stock moving today?

Latest DMRA news — Nov 6, 2026: Guggenheim Keeps Buy Rating on Damora Therapeutics · Nov 6, 2026: H.C. Wainwright keeps Buy rating and $45 target on Damora Therapeutics

What is the DMRA price target?

The average analyst price target for DMRA is $42.50, ranging from $40 to $60, based on 6 analysts.

What do analysts rate DMRA?

Analyst ratings for DMRA: 0 Buy, 8 Hold, 0 Sell — consensus Hold.

Did DMRA beat earnings?

DMRA last reported on Aug 11, 2026: EPS -$0.39 vs -$0.41 expected — a beat of 5.8%.

Does DMRA pay a dividend?

DMRA does not currently pay a dividend.

How much debt does DMRA have?

Galecto, Inc. reported $1M of debt and $14M of cash (Dec 31, 2024).

What are DMRA support and resistance levels?

Support: $23.21, $20.75, $17.49. Resistance: $25.63, $29.18, $31.77.

What are insiders doing with DMRA?

Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.

What is the latest news on DMRA?

Nov 6, 2026: Guggenheim Keeps Buy Rating on Damora Therapeutics · Nov 6, 2026: H.C. Wainwright keeps Buy rating and $45 target on Damora Therapeutics · Nov 6, 2026: Guggenheim keeps Buy rating on Damora Therapeutics, cuts target to $59